Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Vision and balance: new exercise study seeks volunteers

NCT ID NCT07380256

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a balance exercise called IVA is safe and helpful for adults who have vision problems, with or without inner-ear balance issues. Researchers will compare two groups: people with vision problems only and those with both vision and inner-ear problems. Participants will do balance exercises and take tests to see if their eye reflexes, balance, and walking improve.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: For All Participants (All Groups) * Age 18 to 60 years * Able to provide informed consent Group-Specific Inclusion Criteria: * Group 1: Abnormal Uncorrected Static Visual Acuity (No Vestibular Hypofunction) Normal peripheral vestibular function * Group 2: Abnormal Uncorrected Static Visual Acuity + peripheral Vestibular Hypofunction * Group 3: Binocular Vision Abnormalities (No Vestibular Hypofunction) Normal peripheral vestibular function * Group 4: Binocular Vision Abnormalities + peripheral Vestibular Hypofunction Individuals who have abnormal static visual acuity, a binocular vision abnormality (ocular misalignment, convergence insufficiency), and vestibular loss will be assigned to Group 4. The following definitions will be used when determining group placement: * Abnormal Static Visual Acuity: Uncorrected visual acuity (head is still) ≥0.30 logMAR in both eyes. * Unilateral Vestibular Hypofunction: 60 ms VOR gain \<0.80 unilaterally for the lateral semicircular canal. * Bilateral Vestibular Hypofunction: 60 ms VOR gain \<0.80 bilaterally for the lateral semicircular canals. * Normal Vestibular Function: 60 ms VOR gain of 0.80 to 1.20 bilaterally for the lateral semicircular canals. * Convergence Insufficiency: ≥6 cm near point of convergence. * Ocular Misalignment: ≥4 prism diopters of manifest deviation of the eyes (tropia) on cover/uncover testing. Exclusion Criteria: * Diagnosis of fluctuating vestibular disorders (e.g., benign paroxysmal positional vertigo) * Neurologic conditions (e.g., multiple sclerosis), dementia, * Alcohol or drug abuse, * A major psychiatric disorder (e.g., schizophrenia), * Pain that limits cervical spine range of motion by \>50% or that results in an -altered gait pattern.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Binocular vision abnormalities are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Dizziness and Balance Center

    RECRUITING

    Atlanta, Georgia, 30329, United States

  • Emory Ophthalmology Clinics

    NOT_YET_RECRUITING

    Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.